The price of Cidara Therapeutics Inc (NASDAQ: CDTX) closed at $0.76 in the last session, up 6.85% from day before closing price of $0.71. In other words, the price has increased by $+0.0489 from its previous closing price. On the day, 878526 shares were traded.
Ratios:
We take a closer look at CDTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.55 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.41.
On September 22, 2021, WBB Securities Upgraded its rating to Strong Buy which previously was Buy but kept the price unchanged to $6.25.
On March 04, 2021, Aegis Capital started tracking the stock assigning a Buy rating and target price of $9.Aegis Capital initiated its Buy rating on March 04, 2021, with a $9 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 11 ’24 when Tari Leslie sold 21,029 shares for $0.67 per share. The transaction valued at 14,085 led to the insider holds 258,681 shares of the business.
Sandison Taylor sold 20,662 shares of CDTX for $13,839 on Mar 11 ’24. The Chief Medical Officer now owns 347,095 shares after completing the transaction at $0.67 per share. On Mar 11 ’24, another insider, Ward Shane, who serves as the COO & CLO of the company, sold 20,473 shares for $0.67 each. As a result, the insider received 13,713 and left with 198,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDTX now has a Market Capitalization of 69.15M and an Enterprise Value of 24.84M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.22 while its Price-to-Book (P/B) ratio in mrq is 8.58. Its current Enterprise Value per Revenue stands at 0.44 whereas that against EBITDA is -0.81.
Stock Price History:
Over the past 52 weeks, CDTX has reached a high of $2.10, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 0.7011, while the 200-Day Moving Average is calculated to be 0.8684.
Shares Statistics:
According to the various share statistics, CDTX traded on average about 713.47K shares per day over the past 3-months and 631.07k shares per day over the past 10 days. A total of 90.62M shares are outstanding, with a floating share count of 81.82M. Insiders hold about 9.71% of the company’s shares, while institutions hold 29.88% stake in the company. Shares short for CDTX as of Feb 29, 2024 were 221.35k with a Short Ratio of 0.31, compared to 594.45k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.24% and a Short% of Float of 0.25%.
Earnings Estimates
The company has 3 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.16, while EPS last year was -$0.19. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.28 and -$0.36 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$0.58, with 3 analysts recommending between -$0.38 and -$0.7.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $11.54M. It ranges from a high estimate of $14M to a low estimate of $6.7M. As of the current estimate, Cidara Therapeutics Inc’s year-ago sales were $10.22M, an estimated increase of 12.90% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $13.05M, a decrease of -49.80% less than the figure of $12.90% in the same quarter last year. There is a high estimate of $14.5M for the next quarter, whereas the lowest estimate is $11.6M.
A total of 3 analysts have provided revenue estimates for CDTX’s current fiscal year. The highest revenue estimate was $60.3M, while the lowest revenue estimate was $53M, resulting in an average revenue estimate of $57.85M. In the same quarter a year ago, actual revenue was $64.29M, down -10.00% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $21.07M in the next fiscal year. The high estimate is $29.5M and the low estimate is $5.8M. The average revenue growth estimate for next year is down -63.60% from the average revenue estimate for this year.
